ReviewEuropean urology open science2025
Diagnostic Accuracy of Indocyanine Green-stained Sentinel Lymph Nodes in Prostate Cancer Patients: A Systematic Review and Meta-analysis.
Review in European urology open science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Prognostic factors and the role of pelvic lymph node dissection in oligometastatic prostate cancer: a multicenter exploratory study.Surgical endoscopy · 2026Article
- Nerve-Sparing in High-Risk Prostate Cancer: Advantages and Pitfalls of Current Strategies and Technologies.Cancers · 2026Review
- Cystoscopic ICG-Guided Sentinel Lymph Node Dissection in Robotic Radical Prostatectomy: A Prospective Study.The Prostate · 2026Article
- Feasibility of Anti-CEA Dye Conjugate for Cancer-Specific Imaging in Gastric Cancer Cell Lines and Mouse Xenograft Models.Cancers · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective: Indocyanine green-guided sentinel lymph node dissection (ICG-SLND) has demonstrated good diagnostic accuracy for lymph node metastasis in prostate cancer. This study aims to perform a meta-analysis of the diagnostic accuracy of ICG-SLND at both the per-patient and the per-node level. Methods: We conducted a literature search on PubMed and Embase for relevant studies published up to June 2024. The inclusion criteria were prostate cancer patients undergoing radical prostatectomy, ICG-SLND, and subsequent extended pelvic lymph node dissection (ePLND). Data were extracted to calculate the pooled sensitivity and negative predictive value (NPV) at both the per-patient and the per-node level. Key findings and limitations: Our search identified 13 relevant studies, comprising a total of 748 patients. All studies were assessed as having a low risk of bias. At the per-patient level, the pooled sensitivity of ICG-SLND for diagnosing lymph node metastasis was 0.87 (95% confidence interval [CI]: 0.77-0.92), with a pooled NPV of 0.95 (95% CI: 0.90-0.98). At the per-node level, the pooled sensitivity was 0.53 (95% CI: 0.45-0.62), and the pooled NPV was 0.98 (95% CI: 0.97-0.98). Significant heterogeneity was observed in the per-node level sensitivity, NPV, and sentinel lymph node detection rate outcomes. The primary limitation is the lack of investigation into the impact of ICG-SLND on survival outcomes. Conclusions and clinical implications: The per-patient level sensitivity of ICG-SLND for diagnosing lymph node metastases is 87%, which better represents the diagnostic accuracy of ICG-SLND than the per-node level sensitivity. As ePLND has demonstrated a positive impact on oncologic outcomes, ICG-SLND cannot yet be recommended as the standard lymph node dissection approach. The significant heterogeneity observed in the pooled results highlights the need for further research to determine the optimal injection methods. Patient summary: Indocyanine green-guided sentinel lymph node dissection (ICG-SLND) has demonstrated favorable performance for diagnosing lymph node metastases in prostate cancer. The per-patient level sensitivity of ICG-SLND provides better diagnostic performance than its per-node level sensitivity. However, further research is needed for ICG-SLND to be recommended as the standard approach for lymph node dissection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.